Lilly’s $400 Billion Surge Reshapes Big Pharma, Rally
Eli Lilly has added roughly $400 billion in market value over the past year, fueling a dramatic shift in Big Pharma a...
New to investing? Check out these zero fee investment apps designed specifically for new investors to start building wealth.
28,005 articlesEli Lilly has added roughly $400 billion in market value over the past year, fueling a dramatic shift in Big Pharma a...
Discover two AI stocks that Wall Street analysts believe could move significantly higher. Learn what makes them stron...
Johnson & Johnson and AbbVie report divergent quarterly results, fueling a debate about two paths to pharma dominance...
A gold miner’s stock has doubled in 12 months and just raised its dividend by 60%. This deep-dive explains what drive...
Institutional moves can reveal much about a company’s future. This article breaks down why long path partners buys Al...
A major insider sale at LegalZoom prompts questions for investors. This guide breaks down what the move could mean, h...
Oil tensions in the Persian Gulf push crude prices higher while automakers reassess EV investments. Investors are ask...
This article lays out a grounded three-year path for Tesla, focusing on core EV leadership, software-based autonomy r...
Nvidia and Micron are central to AI data centers, but one may be the better buy for your portfolio. This guide breaks...
Tesla stock can swing on headlines and catalysts. This guide shows you how to decide whether you should wait tesla st...
CrowdStrike has become a pillar in AI-era cybersecurity, but a 14% decline raises the question: is it a buy? This gui...
The rumor of a SpaceX IPO is stirring chatter across Wall Street and Main Street alike. If true, spacex could trigger...